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	 A	 new	 sensitive,	 simple,	 rapid,	 accurate	 and	 precise	 spectrofluorimetric	 method	 for
determination	of	diflunisal	and	its	impurity	is	developed.	Determination	of	diflunisal	is	based
on	first	derivative	spectrofluorimetric	method,	while	its	impurity	can	be	determined	by	zero
order	 spectrofluorimetric	 method.	 Diflunisal	 was	 measured	 at	 zero‐crossing	 wavelength
394nm	 (zero	 crossing	 point	 with	 its	 impurity)	 which	 was	 selected	 for	 quantification	 of
diflunisal.	The	impurity	was	measured	directly	at	334	nm,	using	0.05	M	phosphate	buffer	(pH
=	9)	as	 solvent.	The	analytical	 signal	 resulting	 from	 first	 derivative	and	zero	order	 spectra
were	measured	for	diflunisal	and	its	impurity,	respectively.	Linearity	was	over	the	range	of
0.1‐0.9	μg/mL	for	both	with	detection	limit	of	0.02	and	0.03	μg/mL	and	quantitation	limit	of
0.07	and	0.09	μg/mL	for	diflunisal	and	its	impurity,	respectively.	The	proposed	method	was
validated	as	per	ICH	guidelines.The	accuracy	was	checked	by	applying	the	proposed	method
for	 the	 determination	 of	 the	 drug	 and	 its	 impurity,	 the	mean	 percentage	 recoveries	 were
found	to	be	99.61±0.911	and	100.41±1.373	for	diflunisal	and	its	impurity,	respectively.	RSD
values	 for	 repeatability	 testing	were	0.268	 and	 0.569	 and	 for	 intermediate	precision	were
0.224	 and	 0.259	 for	 diflunisal	 and	 its	 impurity,	 respectively.	 The	 proposed	 method	 was
effectively	applied	to	analysis	of	studied	drug	in	its	tablet	formulation.	The	results	obtained
by	it	were	statistically	compared	with	the	reported	method	revealing	high	accuracy	and	good
precision.	
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1.	Introduction	
	
Diflunisal	(DIF)	is	a	salicylic	acid	derivative	with	analgesic	
and	anti‐inflammatory	activity	designated	as	2',	4’‐difluoro‐4‐
hydroxybiphenyl‐3‐carboxylic	 acid.	DIF	 acts	 by	 inhibiting	 the	
production	of	prostaglandin’s	hormones	which	are	involved	in	
inflammation	 and	 pain.	 DIF	 is	 an	 official	 drug	 in	 the	 British	
Pharmacopoeia	 (BP)	 [1]	 (Figure	 1a).	 According	 to	 BP,	
biphenyl‐4‐ol	is	the	major	impurity	of	DIF	(Figure	1b)	[1].	
Different	methods	for	determination	of	DIF	were	reported.	
The	methods	 include	 liquid	 chromatography	 (LC)	 [2‐6],	 TLC‐
densitometry	[7],	gas	chromatography	[8],	spectrophotometry	
[9,10]	 and	 spectrofluorimetry	 [11‐13].	 Reviewing	 the	 litera‐
ture	in	hand,	there	was	no	method	found	for	the	determination	
of	DIF	in	presence	of	its	impurity.	
Spectrofluorimetric	 method	 proved	 to	 be	 more	 selective	
than	normal	UV‐spectroscopy	due	to	quantitation	of	substance	
at	 characteristic	 excitation	 and	 emission	 wavelengths.	
Derivative	 spectrofluorimetry	 provides	 a	 greater	 selectivity	
and	 spectral	 discrimination	 than	 common	spectrofluorimetry	
[14,15].	It	is	a	powerful	approach	for	resolution	of	one	analyte	
whose	peak	 is	hidden	by	a	 large	overlapping	peak	of	another	
analyte	in	multi‐component	analysis.	The	aim	of	the	presented	
work	 was	 to	 develop	 simple,	 economic,	 sensitive	 and	 rapid	
method	 for	 the	 simultaneous	 quantitative	 determination	 of	
both	DIF	and	its	 impurity	(BPL)	 in	bulk	powder	and	in	 tablet	
dosage	 form	 by	 first	 derivative	 and	 zero	 order	
spectrofluorimetry,	 respectively,	 based	 on	 their	 native	
fluorescence.	
	
2.	Experimental	
	
2.1.	Apparatus	
	
Cary	 Eclipse	 fluorescence	 spectrophotometric	 (USA)	
connected	 to	 IBM‐PC	computer	 and	HP	Laser	 Jet	1100	series	
printer.	 The	 emission	 of	 all	 samples	 was	 recorded	 against	 a	
solvent	 blank	 in	 1	 cm	 quartz	 cuvettes	 and	 scanning	 at	 the	
following	 parameters:	 Band	 width	 =	 1.5	 nm,	 Scan	 speed	 =	
1200	 nm/min,	 Data	 Interval	 =	 normal	 (1	 nm),	 Smoothing	 =	
high.	
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(a)	
(b)	
Figure	1.	Chemical	structure	of	diflunisal	(a)	and	biphenyl‐4‐ol	(b).	
	
	
2.2.	Chemicals	and	reagents	
	
All	 chemicals	 and	reagents	used	were	of	analytical	grade.	
Diflunisal	 and	 BPL	 were	 kindly	 provided	 from	 Rameda	
Pharmaceutical	 Company,	 Egypt.	 Its	 purity	 was	 found	 to	 be	
98.96%	 based	 on	 the	 company	 analysis	 certificate.	 Sodium	
dihydrogen	orthophosphate,	methanol,	sodium	hydroxide	and	
acetonitrile	 were	 purchased	 from	 Sigma	 Aldrich	 (Germany).	
APO‐Diflunisal®	 500	 tablets	 manufactured	 by	 Apotex	
Pharmaceutical	 Company	 (Batch	 number:	 KE8472)	 was	
purchased	from	Canada.	
	
2.3.	Procedure	
	
2.3.1.	Stock	standard	solutions	of	DIF	and	BPL	(1	mg/mL)	
	
DIF	(100	mg)	and	BPL	(100	mg)	were	accurately	weighed	
and	 transferred	 into	 two	 separate	 100	mL	 volumetric	 flasks	
and	dissolved	in	5mL	0.05M	phosphate	buffer,	separately.	The	
flasks	 were	 shaken	 and	 volume	 was	 completed	 with	 0.05M	
phosphate	buffer	(pH	=	9).		
	
2.3.2.	Working	standard	solutions	of	DIF	and	BPL	
	
From	 the	 two	 standard	 stock	 solutions,	 10	 mL	 was	
transferred	 from	 each	 to	 two	 separate	 100	 mL	 volumetric	
flasks;	 the	 volume	 was	 completed	 to	 100	 mL	 with	 0.05	 M	
phosphate	 buffer	 (pH	 =	 9)	 to	 obtain	 a	 standard	 working	
solution	 of	 DIF	 and	 BPL	 having	 final	 concentration	 of	 100	
μg/mL	of	each.	
	
2.3.3.	Construction	of	calibration	curve	
	
Aliquots	from	working	standard	solutions	equivalent	to	1‐
9	µg	of	DIF	and	BPL	were	 transferred	 into	two	sets	of	10	mL	
volumetric	 flasks.	 The	 volumes	 were	 completed	 with	 the	
buffer	 to	 obtain	 a	 series	 of	 concentrations	 of	 0.1‐0.9	 µg/mL.	
The	 zero	 order	 spectra	 (D0)	 of	 each	 dilution	 of	 the	 impurity	
were	 recorded,	 and	 then	 peak	 amplitudes	were	measured	 at	
emission	wavelength	of	334	nm	after	excitation	at	254	nm	and	
plotted	against	corresponding	concentrations.	First	derivative	
spectrofluorimetry	 was	 computed	 for	 DIF	 and	 the	 peak	
amplitudes	were	measured	at	394	nm	and	plotted	against	the	
corresponding	concentrations.	The	concentrations	of	the	drug	
and	its	impurity	were	calculated	each	from	the	corresponding	
calibration	curve	equation.	
	
2.3.4.	Pharmaceutical	dosage	form	
	
Ten	tablets	of	marketed	formulation	APO‐Diflunisal®;	each	
containing	500	mg	of	DIF	was	 taken	and	accurately	weighed.	
Average	weight	was	determined	and	tablets	were	crushed	into	
fine	 powder.	 An	 accurately	 weighed	 quantity	 of	 powder	
equivalent	to	100	mg	DIF	was	transferred	to	volumetric	flask	
of	 100mL	 capacity,	 0.05	 M	 phoshate	 buffer	 was	 added,	 the	
flask	 was	 sonicated	 for	 15	 min.	 The	 volume	 was	 completed	
with	 0.05	 M	 phosphate	 buffer.	 The	 solution	 was	 filtered	
through	 Whatmann	 filter	 paper	 (No.	 41).	 The	 solution	 was	
filtered	 and	 diluted	 to	 obtain	 100	 µg/mL	 working	 solution.	
Linearity	procedure	was	followed	and	the	drug	concentration	
was	 calculated	 from	 the	 corresponding	 regression	 equation.	
The	validity	of	the	method	was	assessed	through	applying	the	
standard	 addition	 technique	 by	 mixing	 different	 concent‐
rations	 of	 the	 standard	 drug	 to	 a	 fixed	 amount	 of	 its	
formulation.	 The	 concentrations	 of	 standard	 added	 were	
calculated	from	the	corresponding	regression	equations.	
	
3.	Results	and	discussion	
	
Derivative	 spectrofluorimetry	 offers	 greater	 selectivity	
than	 normal	 spectrophotometry	 for	 simultaneous	 determi‐
nation	of	 two	or	more	compounds	without	previous	chemical	
separation	 [16].	 The	 presented	 spectrofluorimetric	 method	
was	applied	for	quantitative	determination	of	DIF	and	BPL	in	
pure	 form	 and	 tablet	 dosage	 form.	 DIF	 exhibits	 native	
fluorescence	 at	 emission	 wavelength	 of	 426	 nm	 after	
excitation	 at	 257	 nm	 (Figure	 2),	 while	 BPL	 exhibits	 fluore‐
scence	 at	 emission	wavelength	 of	 334	 nm	 after	 excitation	 at	
254	nm	in	0.05	M	phosphate	buffer	(Figure	3).	The	zero	order	
emission	 spectra	 of	 DIF	 with	 BPL	 revealed	 some	 spectral	
overlap	as	shown	in	Figure	4.	Zero	order	spectra	showed	that	
the	 impurity	 could	 be	 determined	 by	 measuring	 the	 peak	
amplitude	at	334	nm	without	any	 interference	 from	DIF.	The	
first	derivative	spectra	of	DIF	and	BPL	showed	that	DIF	could	
be	determined	by	measuring	the	peak	amplitude	at	394	nm	for	
DIF	without	any	 interference	from	BPL	as	shown	in	Figure	5.	
Linear	relationships	were	found	in	the	range	0.1‐0.9	µg/mL	for	
both	 DIF	 and	 BPL	 by	 first	 derivative	 spectroflourimetry	 and	
zero	order	spectrofluorimetric	method,	respectively.	
	
	
	
Figure	2.	Excitation	and	emission	spectra	of	diflunisal	(0.4	μg/mL)	in	0.05	
M	phosphate	buffer.	
	
The	regression	equation	 for	DIF	and	BPL	were	computed	
and	found	to	be:	
	
At	λ394	nm;	y	=	24.6549x	+0.0364		 r	=	0.9997	for	DIF	 (1)	
	
At	λ334	nm;	y	=	571.7890x	+	96.5248		 r	=	0.9998	for	imp.	 (2)	
	
where	y	is	the	peak	intensity,	x	is	the	concentration	in	μg/mL	
and	r	is	the	correlation	coefficient.	
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Table	1.	Regression	and	analytical	parameters	of	the	proposed	spectroflourimetry	method	for	determination	of	diflunisal	and	its	impurity.	
Parameters	 DIF	by	first	derivative Impurity	by	zero	order	
Linearity	
Calibration	range,	µg/mL	 0.1‐0.9	 0.1‐0.9		
Slope	 24.6549	 571.7890	
Intercept	 0.0364	 96.5248	
Correlation	coefficient	(r)	 0.9997	 0.9998	
Accuracy	(mean±%RSD)	 99.61±0.911 100.41±1.375	
Precision	(%RSD)	
Repeatability	a	 0.268	 0.569	
Intermediate	precision	b	 0.224	 0.259	
LOD,	µg/mL	 0.022	 0.031	
LOQ,	µg/mL	 0.067 0.094	
a	The	intra‐day	(n	=	9)	average	of	three	different	concentrations	(0.1,	0.2	and	0.5	μg/mL)	repeated	three	times	within	1	day.	
b	The	inter‐day	(n	=	9)	average	of	three	different	concentrations	(0.1,	0.2	and	0.5	μg/mL)	repeated	three	times	in	3	successive	days.	
	
	
Table	 2.	 Statistical	 comparison	 of	 the	 results	 obtained	 by	 applying	 the	 proposed	 spectroflourimetry	 method	 and	 the	 official	 titrimetric	 method	 for	
determination	of	DIF	in	pure	form.	
Parameters	 Spectroflourimetric	method Official method	a	
Mean	 100.01 99.76
S.D.	 0.762 0.761
n	 10	 6	
Student´s	t‐test	 0.301	(2.160)	 ‐	
F‐test	 1.433	(5.990)	 ‐	
a	BP	acid	base	titration	method	[1],	The	values	between	parentheses	represent	the	corresponding	tabulated	values	of	t	and	F	at	p	=	0.05.	
	
	
	
	
	
Figure	3.	 Excitation	and	 emission	 spectra	 of	 biphenyl‐4‐ol	 (0.4	μg/mL)	 in	
0.05	M	phosphate	buffer.	
	
	
	
	
	
Figure	4.	 	Zero	order	emission	spectra	of	0.4	μg/mL	diflunisal	(Black),	0.4	
μg/mL	 of	 the	 impurity	 (Red)	 and	mixture	 of	 0.4	 μg/mL	diflunisal	 and	 0.4	
μg/mL	of	BPL	(Green)	in	0.05	M	phosphate	buffer	(pH	=	9).		
	
	
	
	
	
Figure	5.	First	derivative	emission	spectra	of	0.9	μg/mL	diflunisal (A) and	
0.9	μg/mL	of	BPL	(B)	in	0.05	M	potassium	phosphate	buffer	(pH	=	9).	
	
The	 LOD	 and	 LOQ	 for	 DIF	 were	 found	 to	 be	 0.022	 and	
0.067	µg/mL,	respectively,	and	0.031	and	0.094	µg/mL	for	BPL	
respectively,	Table	1.	 	 	 	
The	proposed	method	was	 applied	 for	 the	 determination	
of	pure	 sample	 of	DIF	 and	BPL	over	 the	 concentration	 range	
0.1‐0.9	µg/mL	in	order	to	determine	accuracy	of	the	proposed	
method.	The	results	obtained	are	summarized	in	Table	1.	
The	 results	 obtained	 by	 applying	 the	 proposed	 first	
derivative	 spectrofluorimetric	method	 for	 the	 analysis	 of	 the	
studied	compound	in	pure	drug	sample	and	dosage	form	were	
statistically	compared	to	the	official	BP	method	[1].	The	values	
of	the	calculated	t	and	F	are	less	than	the	tabulated	ones	which	
reveal	 that	 there	 is	 no	 significant	 difference	 with	 respect	 to	
accuracy	and	precision	as	shown	in	Table	2.	The	method	was	
used	 for	determination	of	 the	dosage	 form	and	accuracy	was	
further	 assessed	 by	 application	 of	 the	 standard	 addition	
technique,	 the	 results	 are	 summarized	 in	Table	 3.	 The	 speci‐
ficity	 of	 the	 proposed	 first	 derivative	 spectrofluorimetric	
method	for	DIF	and	zero	order	method	for	the	impurity	were	
emphasized	 by	 analyzing	 laboratory	 prepared	 mixtures	
containing	 different	 percentage	 of	 each	 drug	 with	 BPL.	 The	
method	was	valid	in	the	presence	of	up	to	100%	of	BPL	for	DIF	
as	shown	in	Table	4.	
	
3.1.	Optimization	of	method	
	
Different	solvents	and	systems	were	tested	in	order	to	find	
the	 best	 conditions	 like	 solubility,	 fluorescence	 intensity,	
stability	 and	 spectral	discrimination	 (clear	 separation)	of	 the	
drug	and	BPL.	
	
3.1.1.	Excitation	and	emission	spectra		
	
Scanning	 of	 excitation	 and	 emission	 spectra	was	 done	 to	
obtain	 the	 optimum	 wavelengths	 for	 the	 resolution	 of	 the	
mixture.	 DIF	 can	 be	 determined	 at	 394	 nm	 using	 first	
derivative	 fluorimetric	 method	 and	 its	 impurity	 can	 be	
determined	 at	 334	 using	 zero	 order	 spectrofluorimetric	
method.	
	
3.1.2.	Effect	of	solvents	
	
Different	 solvents	 were	 used	 to	 measure	 the	 maximum	
fluorescence	 intensity	 as	 acetonitrile,	 water,	 0.1	 M	 sodium	
hydroxide,	methanol	and	0.05	M	phosphate	buffer.	
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Table	3.	Determination	of	diflunisal	in	Apo‐diflunisal®	tablets	by	the	proposed	spectroflourimetry	method	and	results	of	standard	addition.	
Pharmaceutical	
Formulation	
Taken	
(µg/mL)	
%Found±RSD	a	
	
Standard	addition	technique
Pure	added	(µg/mL) Recovery	%	a
Apodiflunisal®	tablets	 0.4	 101.00±0.762 0.3 99.00	
0.4	 101.25	
0.5 98.60	
Mean±%RSD 99.62%±1.429
a	Average	of	3	determinations.	
	
	
Table	4.	Specificity	of	the	proposed	FDF	method	and	zero	order	method	for	the	determination	DIF	and	BPL	in	laboratory	prepared	mixtures	
Mixture	
no.	
DIF	 Impurity	
Claimed	taken	(μg/mL)	 Found	(μg/mL) Recovery	%	a Claimed	taken (μg/mL) Found	(μg/mL)	 Recovery	%	a
1	 0.1	 0.099	 99.00 0.9 0.902 100.22	
2	 0.2	 0.195	 99.50 0.7 0.710 101.43	
3	 0.4	 0.407	 101.94 0.4 0.395 98.75	
4	 0.7	 0.701	 100.14 0.3 0.305 101.67	
5	 0.9	 0.891	 99.00 0.1 0.991 99.00	
Mean±S.D.	 99.72±1.38 100.41±1.61
a	Average	of	3	determinations.	
	
	
The	maximum	fluorescence	intensity	was	observed	in	0.05	
M	phosphate	buffer,	pH	=	9.	
	
3.1.3.	Effect	of	pH	
	
The	 fluorescence	 intensity	 of	 diflunisal	 solutions	 was	
measured	over	a	pH	 range	 from	4.0	 to	13.5,	by	using	0.05	M	
phosphate	buffer	and	adjusting	the	pH	with	hydrochloric	acid	
and	 sodium	hydroxide	 solutions.	 The	maximum	 fluorescence	
intensity	was	observed	at	pH	=	9.		
	
3.2.	Method	validation	
	
Validation	was	done	according	to	International	Conference	
on	Harmonization	(ICH)	guidelines	[17].	
	
3.2.1.	Linearity	
	
Under	 optimum	 experimental	 conditions,	 DIF	 and	 BPL	
were	determined	 in	 triplicates	 in	 the	 range	 of	 0.1‐0.9	 µg/mL	
for	 both	 for	 first	 derivative	 spectrofluorimetric	 method	 and	
zero	 order	 spectrofluorimetric	 method,	 respectively.	 The	
linearity	 of	 the	 calibration	 graphs	 were	 validated	 and	 the	
regression	equations	were	then	computed,	Table	1.	
	
3.2.2.	Accuracy	
	
Pure	samples	of	DIF	and	its	impurity	were	analyzed	by	the	
proposed	method;	the	mean	percentage	recoveries	were	then	
calculated.	 The	 accuracy	 was	 further	 assessed	 by	 standard	
addition	 technique.	 It	 was	 done	 by	 spiking	 the	 pre‐analyzed	
DIF	 sample	 0.4µg/mL	 with	 an	 extra	 0.3,	 0.4,	 and	 0.5	 of	
standard	DIF.	The	experiment	was	conducted	in	triplicate.	The	
percentage	 recovery	 and	 percentage	 relative	 standard	
deviation	 (%	 RSD)	 were	 calculated	 for	 each	 concentration,	
Table	3.	
	
3.2.3.	Precision	
	
3.2.3.1.	Repeatability	(intra‐assay	precision)	
	
It	was	evaluated	by	assaying	freshly	prepared	solutions	in	
triplicateon	the	same	day	at	concentrations	of	(0.1,	0.2	and	0.5	
μg/mL)	for	DIF	and	(0.1,	0.3	and	0.5	μg/mL)	for	its	impurity	to	
determine	intraday	variation.	
	
3.2.3.2.	Intermediate	precision	
	
The	 previous	 procedures	 were	 repeated	 for	 the	 same	
concentrations	 three	 times	 on	 three	 consecutive	 days	 to	
determine	 precision	 (inter‐day).	 The	 results	 and	 relative	
standard	deviations	(%RSD)	were	calculated,	Table	1.	
3.2.4.	Specificity	
	
Specificity	 is	 the	 ability	 to	 measure	 accurately	 and	
specifically	 the	 analyte	 of	 interest	 in	 the	 presence	 of	 other	
components.	Synthetic	mixtures	of	drug	and	its	impurity	were	
prepared.	 Aliquots	 equivalent	 to	 9‐1	 µg/mL	 of	 DIF	 were	
separately	 transferred	 from	 their	working	standard	solutions	
into	10	mL	volumetric	flask.	To	the	previous	solutions	aliquots	
equivalent	 to	 1‐9	 µg/mL	 of	 BPL	 were	 added	 from	 their	
working	standard	solutions	and	the	volume	was	completed	to	
the	mark	with	the	buffer.	The	concentrations	of	the	intact	drug	
and	 its	 impurity	 were	 calculated	 from	 its	 corresponding	
regression	equations,	Table	4.	
	
3.2.5.	Limit	of	detection	(LOD)	and	limit	of	quantitation	
(LOQ)	
	
LOD	is	the	lowest	concentration	of	an	analyte	in	a	sample	
that	 can	be	detected	 and	 calculated	by	 the	 following	 formula	
LOD	=	3.3×(SD/S)	where	SD	is	the	standard	deviation	and	S	is	
the	 slope.	 LOQ	 is	 the	 lowest	 concentration	 of	 an	 analyte	 in	 a	
sample	that	can	be	determined	with	acceptable	precision	and	
accuracy	 under	 the	 stated	 experimental	 conditions	 of	 the	
method	LOD	=	10×(SD/S).	
	
4.	Conclusion	
	
From	 the	 data	 obtained,	 it	 is	 noted	 that	 the	 proposed	
method	 is	 accurate,	 precise,	 and	 specific	 over	 defined	 range	
and	 could	 be	 used	 for	 purity	 testing,	 quality	 control	 and	
routine	 analysis	 of	 DIF	 in	 pure	 and	 in	 dosage	 forms.	 The	
advantages	 of	 the	 proposed	 method	 are	 low	 cost,	 rapidity,	
sensitivity	 and	 environmental	 protection.	 It	 is	 suitable	 for	
quality	 control	 laboratories	 where	 economy	 and	 time	 are	
essential.	 The	 spectrofluorimetric	method	was	 applicable	 for	
assay	 and	 purity	 testing	 of	 DIF	 in	 bulk	 and	 pharmaceutical	
formulations	 without	 interference	 of	 additives	 in	 the	
pharmaceutical	 preparation.	 It	 also	 can	 determine	 the	
impurity	of	DIF	in	trace	concentrations,	so	it	can	be	applied	to	
detect	 very	 low	 extent	 of	 impurity	 of	 DIF	 and	 no	 previously	
published	method	approached	that.	
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